tiprankstipranks

John Mendlein Insider Profile

11 Followers
John Mendlein, Director at Fate Therapeutics, holds 311.23K shares in Fate Therapeutics (Ticker: FATE), holds ― shares in Editas Medicine (Ticker: EDIT), holds 615.38K shares in aTyr Pharma (Ticker: LIFE). Most recently, John Mendlein Bought ― shares of Fate Therapeutics on Jan 20, 2023 for an estimated value of 38.99K.
tipranks
John Mendlein

John Mendlein
Fate Therapeutics (FATE)
Director

Ranked #38,572 out of 98,743 Corporate Insiders

Profitable Transactions

25%
1 out of 4 Profitable Transactions

Average Return

+4.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$2M
54.98%
45.02%
0.00%
0.00%
A breakdown of John Mendlein's holdings

Insider Roles

Fate Therapeutics
(FATE)
Director
aTyr Pharma
(LIFE)
Director
Editas Medicine
(EDIT)
Director
Omega Therapeutics
(OMGA)
Director
Roles that John Mendlein holds in companies

Most Profitable Insider Trade

Stock:
Fate Therapeutics
(FATE)
Rating:Informative Sell
Date:Jun 06, 2022 - Jun 06, 2023
Return:+75.40%
The most profitable trade made by John Mendlein

John Mendlein's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Fate Therapeutics
Jan 20, 2023
Director
Informative Buy
38.99K
$1.27M
Editas Medicine
Director
aTyr Pharma
Dec 26, 2018
Director
Informative Buy
102.40K
$1.04M
Omega Therapeutics
Director
List of latest transactions for each holding click on a transaction to see John Mendlein's performance on stock

John Mendlein insider profile FAQ

What is the percentage of profitable transactions made by John Mendlein?
The percentage of profitable transactions made by John Mendlein is 25%.
    What is the average return per transaction made by John Mendlein?
    The average return per transaction made by John Mendlein is 4.00%.
      What stocks does John Mendlein hold?
      John Mendlein holds: FATE, EDIT, LIFE, OMGA stocks.
        What was John Mendlein’s latest transaction?
        John Mendlein latest transaction was an Informative Buy of $38.99K.
          What was John Mendlein's most profitable transaction?
          John Mendlein’s most profitable transaction was an Informative Sell of FATE stock on June 6, 2022. The return on the trade was 75.40%.
            What is John Mendlein's role in Fate Therapeutics?
            John Mendlein's role in Fate Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.